Halozyme Stocks Slip 4.28% Despite 39% Revenue Growth and Modestly Higher Guidance
Published . Updated .
Market Call
Think this story will push the stock up or down over the next three trading days? Make a free call and see what other readers think. Points are play money with no cash value.
Get these market calls by email
The week's biggest market-moving stories, Congress trades and Trump posts, with the tickers they touch. Free, one email a week.
Free. We only use your email to send the digest, never sell or share it, and every email has a one-click unsubscribe link. See our privacy policy.
Royalty revenue climbed 44%, but the 2026 revenue guidance midpoint rose only about $20 million.
Directly affected
- HALO Halozyme Therapeutics+14.3% 30d
Named in this report.
Indirectly affected
- DIA SPDR Dow Jones Industrial Average ETF-0.0% 19d
SPDR Dow Jones Industrial Average ETF: it is a broad US stock-market fund. Linked by “stocks” (the broad US market) in this story.
- QQQ Invesco QQQ-9.8% 30d
Invesco QQQ: it is a broad US stock-market fund. Linked by “stocks” (the broad US market) in this story.
- XLV Health Care Select Sector SPDR
Health Care Select Sector SPDR holds the health sector that Halozyme Therapeutics belongs to, so it often moves with news about it.
- AMGN Amgen+17.8% 30d
Amgen is a peer of Halozyme Therapeutics in biological products, (no diagnostic substances); rivals often move on the same news.
- GILD Gilead Sciences+16.3% 30d
Gilead Sciences is a peer of Halozyme Therapeutics in biological products, (no diagnostic substances); rivals often move on the same news.
- MRNA Moderna+25.4% 30d
Moderna is a peer of Halozyme Therapeutics in biological products, (no diagnostic substances); rivals often move on the same news.
- ARGX argenx SE-17.3% 13d
argenx SE is a peer of Halozyme Therapeutics in biological products, (no diagnostic substances); rivals often move on the same news.
- RVMD Revolution Medicines
Revolution Medicines is a peer of Halozyme Therapeutics in biological products, (no diagnostic substances); rivals often move on the same news.
Price reaction, T-5 to T+3
| Ticker | T-5 | T-3 | T-1 | T0 | T+1 | T+2 | T+3 |
|---|---|---|---|---|---|---|---|
| HALO | +6.48% | +4.63% | base | -15.02% | after close | after close | after close |
| DIA | +0.47% | +0.48% | base | +0.04% | after close | after close | after close |
| QQQ | +6.56% | +5.75% | base | +2.01% | after close | after close | after close |
| XLV | -0.05% | -0.52% | base | -0.28% | after close | after close | after close |
| AMGN | +1.22% | +0.14% | base | +0.35% | after close | after close | after close |
| GILD | +2.05% | -0.01% | base | +0.29% | after close | after close | after close |
| MRNA | -8.19% | -5.38% | base | +10.29% | after close | after close | after close |
| ARGX | -0.15% | +0.79% | base | +2.80% | after close | after close | after close |
| RVMD | +7.60% | +9.18% | base | +7.35% | after close | after close | after close |
Closing-price change versus T-1, the last close before the story. T0 to T+3 fill in after each market close. Prices: Alpaca IEX.
Halozyme Stocks Slip 4.28% Despite 39% Revenue Growth and Modestly Higher Guidance Yahoo Finance
Source: Yahoo Finance
This story
| Company | When | Move | Status |
|---|---|---|---|
| AMGN | that day | +0.35% | still updating |
| AMGN | three days earlier | +0.14% | final price |
| AMGN | five days earlier | +1.22% | final price |
| ARGX | that day | +2.80% | still updating |
| ARGX | three days earlier | +0.79% | final price |
| ARGX | five days earlier | -0.15% | final price |
| DIA | that day | +0.04% | still updating |
| DIA | three days earlier | +0.48% | final price |
| DIA | five days earlier | +0.47% | final price |
| GILD | that day | +0.29% | still updating |
| GILD | three days earlier | -0.01% | final price |
| GILD | five days earlier | +2.05% | final price |
| HALO | that day | -15.02% | still updating |
| HALO | three days earlier | +4.63% | final price |
| HALO | five days earlier | +6.48% | final price |
| MRNA | that day | +10.29% | still updating |
| MRNA | three days earlier | -5.38% | final price |
| MRNA | five days earlier | -8.19% | final price |
| QQQ | that day | +2.01% | still updating |
| QQQ | three days earlier | +5.75% | final price |
| QQQ | five days earlier | +6.56% | final price |
| RVMD | that day | +7.35% | still updating |
| RVMD | three days earlier | +9.18% | final price |
| RVMD | five days earlier | +7.60% | final price |
| XLV | that day | -0.28% | still updating |
| XLV | three days earlier | -0.52% | final price |
| XLV | five days earlier | -0.05% | final price |
Trades by members of Congress and officials in the stocks in this story
- Rep. Gilbert Cisneros sold Halozyme Therapeutics (HALO), worth $1,001 - $15,000 on 29 Sep 2026. That is 38 days before publication. Filed 12 Oct 2026. View the filing.
- Rep. David J. Taylor bought Amgen (AMGN), worth $1,001 - $15,000 on 22 Sep 2026. That is 45 days before publication. Filed 1 Oct 2026. View the filing.
- Rep. David J. Taylor sold Amgen (AMGN), worth $1,001 - $15,000 on 26 Aug 2026. That is 72 days before publication. Filed 5 Sep 2026. View the filing.
- Sen. Sheldon Whitehouse sold Amgen (AMGN) (held by a spouse), worth $1,001 - $15,000 on 12 Aug 2026. That is 86 days before publication. Filed 2 Sep 2026. View the filing.
- Rep. Rohit Khanna sold Gilead Sciences (GILD) (held by a dependent child), worth $1,001 - $15,000 on 10 Aug 2026. That is 88 days before publication. Filed 4 Sep 2026. View the filing.
- Rep. Maria Elvira Salazar sold Moderna (MRNA), worth $1,001 - $15,000 on 24 Sep 2026. That is 43 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Rohit Khanna bought Moderna (MRNA) (held by a spouse), worth $1,001 - $15,000 on 4 Sep 2026. That is 63 days before publication. Filed 7 Oct 2026. View the filing.
- Donald J Trump, an executive branch official, bought Moderna (MRNA), worth $1,001 - $15,000 on 28 Aug 2026. That is 70 days before publication. Filed 8 Oct 2026. View the filing.
Public disclosure filings, not a recommendation. The filing link is the source document. News use of these reports still sits under 5 U.S.C. § 13107(c).
This story
12 out of 100Price not final
“Halozyme Stocks Slip 4.28% Despite 39% Revenue Growth and Modestly Higher Guidance” scores 12 out of 100. The score uses 1 sources. The price is not final yet.